• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
GTG
Click for more information
0.00% 3.9¢

GENETIC TECHNOLOGIES LIMITED - Announcements

Market Cap $5.671M  ! watchlist Created with Sketch. Add to my watchlist

Genetic Technologies Limited is an Australia-based diversified molecular diagnostics... Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and morMore

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
GTGFurther patent success in USAPRICE SENSITIVE12/03/14
GTGEconomic modelling supports cost-effectiveness of BREVAGenPRICE SENSITIVE07/03/14
GTGASX Appendix 4D with Financial ReportPRICE SENSITIVE20/02/14
GTGPatent re-examination certificate issuedPRICE SENSITIVE12/02/14
GTGQuarterly Reports - 31 December 2013PRICE SENSITIVE30/01/14
GTGGTG announces continued growth in number of BREVAGen testsPRICE SENSITIVE08/01/14
GTGSettlement with ReprogeneticsPRICE SENSITIVE07/01/14
GTGLicensing update - December 2013PRICE SENSITIVE24/12/13
GTGShare transactions with major shareholderPRICE SENSITIVE18/12/13
GTGTrading HaltPRICE SENSITIVE18/12/13
GTGQuarterly Activites Report and ASX Appendix 4CPRICE SENSITIVE31/10/13
GTGTemporary corporate restructurePRICE SENSITIVE15/10/13
GTGResults of share purchase planPRICE SENSITIVE03/10/13
GTGGTG announces further record number of BREVAGen testsPRICE SENSITIVE01/10/13
GTGTermination of patent re-examinationPRICE SENSITIVE30/09/13
GTGSettlement with Genesis GeneticsPRICE SENSITIVE03/09/13
GTGASX Appendix 4E - 30 June 2013PRICE SENSITIVE30/08/13
GTGGTG receives certification for New York StatePRICE SENSITIVE30/08/13
GTGFund raising updatePRICE SENSITIVE27/08/13
GTGExecution of eighth PPO agreementPRICE SENSITIVE22/08/13
GTGFund raising updatePRICE SENSITIVE01/08/13
GTGAppendix 4C - quarterlyPRICE SENSITIVE30/07/13
GTGTrading HaltPRICE SENSITIVE30/07/13
GTGGtech International executes Merger AgreementPRICE SENSITIVE30/07/13
GTGUS Patent Office allows first US patent to ImmunAidPRICE SENSITIVE10/07/13
GTGSettlement with Reproductive Genetics InstitutePRICE SENSITIVE28/06/13
GTGSettlement with BioscientiaPRICE SENSITIVE24/06/13
GTGExecution of seventh PPO agreementPRICE SENSITIVE19/06/13
GTGGTG executes sixth PPO agreementPRICE SENSITIVE20/05/13
GTGSettlement Agreement executed with LabCorpPRICE SENSITIVE06/05/13
GTGGTG executes fifth PPO agreementPRICE SENSITIVE03/05/13
GTGASX Appendix 4C and quarterly activities reportPRICE SENSITIVE30/04/13
GTGSettlement with Genetics & IVF Institute Inc.PRICE SENSITIVE30/04/13
GTGGTG executes agreement with PreventionGeneticsPRICE SENSITIVE29/04/13
GTGReply to QueryPRICE SENSITIVE17/04/13
GTGLicensing update - March 2013PRICE SENSITIVE19/03/13
GTGUS patent re-examination updatePRICE SENSITIVE15/03/13
GTGHalf-Year results and ASX Appendix 4DPRICE SENSITIVE22/02/13
GTGAppendix 4C - quarterlyPRICE SENSITIVE25/01/13
GTGLicensing update - December 2012PRICE SENSITIVE20/12/12
GTGAppointment of permanent CEO and Non-Executive DirectorPRICE SENSITIVE10/12/12
GTGGTG resolves infringement claim against 454 Life SciencesPRICE SENSITIVE06/12/12
GTGAppointment of Chairman and Acting CEOPRICE SENSITIVE28/11/12
GTGResignationsPRICE SENSITIVE27/11/12
GTGAppendix 4C - quarterlyPRICE SENSITIVE25/10/12
GTGGenetic Technologies files four new infringement suitsPRICE SENSITIVE15/10/12
GTGBREVAGen cleared for sale in FloridaPRICE SENSITIVE25/09/12
GTGGTG executes license with Conexio GenomicsPRICE SENSITIVE06/09/12
GTGGTG files suit against Reproductive Genetics InstitutePRICE SENSITIVE30/08/12
GTG2012 ASX Appendix 4E and audited Financial ReportPRICE SENSITIVE28/08/12
GTGGenetic Technologies receives CE mark approval for BREVAGenPRICE SENSITIVE08/08/12
GTGAppendix 4C - quarterlyPRICE SENSITIVE30/07/12
GTGBREVAGen cleared for sale in CaliforniaPRICE SENSITIVE26/07/12
GTGNon-coding licensing updatePRICE SENSITIVE09/07/12
GTGBREVAGen credentialing updatePRICE SENSITIVE22/05/12
GTGSettlement with GeneSeekPRICE SENSITIVE09/05/12
GTGAppendix 4C - quarterlyPRICE SENSITIVE24/04/12
GTGImmunAid Pty. Ltd. secures cornerstone fundingPRICE SENSITIVE13/04/12
GTGUpdate on US and Australian gene patenting litigationPRICE SENSITIVE29/02/12
GTGHalf Yearly Report and AccountsPRICE SENSITIVE27/02/12
GTG +Conclusion of second patent infringement suitPRICE SENSITIVE21/02/12
GTGGTG receives CLIA Certificate of CompliancePRICE SENSITIVE16/02/12
GTGSettlement with Eurofins STAPRICE SENSITIVE06/02/12
GTGAppendix 4C - quarterlyPRICE SENSITIVE30/01/12
GTGResponse to ASX Price and Volume QueryPRICE SENSITIVE27/01/12
GTGSettlement and License Agreement with AutoImmun DiagnostikaPRICE SENSITIVE01/12/11
GTGImmunAid press releasePRICE SENSITIVE02/11/11
GTGAppendix 4C - quarterlyPRICE SENSITIVE26/10/11
GTGPreliminary Final ReportPRICE SENSITIVE25/08/11
GTGSettlement with Attomol GmbHPRICE SENSITIVE25/08/11
GTGAppendix 4C - quarterlyPRICE SENSITIVE29/07/11
GTGReinstatement to Official QuotationPRICE SENSITIVE22/07/11
GTGCompletion of Successful Capital raisingPRICE SENSITIVE22/07/11
GTGResponse to ASX Price QueryPRICE SENSITIVE22/07/11
GTGSuspension from Official QuotationPRICE SENSITIVE13/07/11
GTGTrading HaltPRICE SENSITIVE12/07/11
GTGSettlement with NavigenicsPRICE SENSITIVE28/06/11
GTGLaunch of BREVAGen test in USPRICE SENSITIVE20/06/11
GTGGTG GENE processes first BREVAGen samplePRICE SENSITIVE31/05/11
GTGShareholder newsletterPRICE SENSITIVE30/05/11
GTGFiling of further patent infringement suitPRICE SENSITIVE26/05/11
GTGResponse to ASX Price and Volume QueryPRICE SENSITIVE11/05/11
GTGAppendix 4C - quarterlyPRICE SENSITIVE28/04/11
GTGGenetic Technologies secures CLIA certificationPRICE SENSITIVE27/04/11
GTGCollaboration with global pharmaceutical companyPRICE SENSITIVE20/04/11
GTGSettlement and License Agreement with ViennaLab DiagnosticsPRICE SENSITIVE14/04/11
GTGSuccessful Conclusion of First Assertion SuitPRICE SENSITIVE13/04/11
GTGSettlement and License Agreement with Orchid Cellmark, Inc.PRICE SENSITIVE11/04/11
GTGHalf Yearly Report and AccountsPRICE SENSITIVE24/02/11
GTGExtension of forensics contractPRICE SENSITIVE09/02/11
GTGAppendix 4C - quarterlyPRICE SENSITIVE28/01/11
GTGMaiden half-year profitPRICE SENSITIVE28/01/11
GTG +Second patent infringement law suit filedPRICE SENSITIVE20/01/11
GTG +Settlement of dispute with Sunrise MedicalPRICE SENSITIVE17/01/11
GTGResponse to ASX QueryPRICE SENSITIVE07/01/11
GTGGranting of license to QiagenPRICE SENSITIVE31/12/10
GTGSettlement of dispute with Pioneer Hi-BredPRICE SENSITIVE30/11/10
GTGGranting of license to Laboratoires ReunisPRICE SENSITIVE23/11/10
GTGSettlement of dispute with Innogenetics NVPRICE SENSITIVE11/11/10
GTGValidation of BREVAGen in Journal of NCIPRICE SENSITIVE28/10/10
GTGFurther patent success in USA
12/03/14PRICE SENSITIVE
GTGEconomic modelling supports cost-effectiveness of BREVAGen
07/03/14PRICE SENSITIVE
GTGASX Appendix 4D with Financial Report
20/02/14PRICE SENSITIVE
GTGPatent re-examination certificate issued
12/02/14PRICE SENSITIVE
GTGQuarterly Reports - 31 December 2013
30/01/14PRICE SENSITIVE
GTGGTG announces continued growth in number of BREVAGen tests
08/01/14PRICE SENSITIVE
GTGSettlement with Reprogenetics
07/01/14PRICE SENSITIVE
GTGLicensing update - December 2013
24/12/13PRICE SENSITIVE
GTGShare transactions with major shareholder
18/12/13PRICE SENSITIVE
GTGTrading Halt
18/12/13PRICE SENSITIVE
GTGQuarterly Activites Report and ASX Appendix 4C
31/10/13PRICE SENSITIVE
GTGTemporary corporate restructure
15/10/13PRICE SENSITIVE
GTGResults of share purchase plan
03/10/13PRICE SENSITIVE
GTGGTG announces further record number of BREVAGen tests
01/10/13PRICE SENSITIVE
GTGTermination of patent re-examination
30/09/13PRICE SENSITIVE
GTGSettlement with Genesis Genetics
03/09/13PRICE SENSITIVE
GTGASX Appendix 4E - 30 June 2013
30/08/13PRICE SENSITIVE
GTGGTG receives certification for New York State
30/08/13PRICE SENSITIVE
GTGFund raising update
27/08/13PRICE SENSITIVE
GTGExecution of eighth PPO agreement
22/08/13PRICE SENSITIVE
GTGFund raising update
01/08/13PRICE SENSITIVE
GTGAppendix 4C - quarterly
30/07/13PRICE SENSITIVE
GTGTrading Halt
30/07/13PRICE SENSITIVE
GTGGtech International executes Merger Agreement
30/07/13PRICE SENSITIVE
GTGUS Patent Office allows first US patent to ImmunAid
10/07/13PRICE SENSITIVE
GTGSettlement with Reproductive Genetics Institute
28/06/13PRICE SENSITIVE
GTGSettlement with Bioscientia
24/06/13PRICE SENSITIVE
GTGExecution of seventh PPO agreement
19/06/13PRICE SENSITIVE
GTGGTG executes sixth PPO agreement
20/05/13PRICE SENSITIVE
GTGSettlement Agreement executed with LabCorp
06/05/13PRICE SENSITIVE
GTGGTG executes fifth PPO agreement
03/05/13PRICE SENSITIVE
GTGASX Appendix 4C and quarterly activities report
30/04/13PRICE SENSITIVE
GTGSettlement with Genetics & IVF Institute Inc.
30/04/13PRICE SENSITIVE
GTGGTG executes agreement with PreventionGenetics
29/04/13PRICE SENSITIVE
GTGReply to Query
17/04/13PRICE SENSITIVE
GTGLicensing update - March 2013
19/03/13PRICE SENSITIVE
GTGUS patent re-examination update
15/03/13PRICE SENSITIVE
GTGHalf-Year results and ASX Appendix 4D
22/02/13PRICE SENSITIVE
GTGAppendix 4C - quarterly
25/01/13PRICE SENSITIVE
GTGLicensing update - December 2012
20/12/12PRICE SENSITIVE
GTGAppointment of permanent CEO and Non-Executive Director
10/12/12PRICE SENSITIVE
GTGGTG resolves infringement claim against 454 Life Sciences
06/12/12PRICE SENSITIVE
GTGAppointment of Chairman and Acting CEO
28/11/12PRICE SENSITIVE
GTGResignations
27/11/12PRICE SENSITIVE
GTGAppendix 4C - quarterly
25/10/12PRICE SENSITIVE
GTGGenetic Technologies files four new infringement suits
15/10/12PRICE SENSITIVE
GTGBREVAGen cleared for sale in Florida
25/09/12PRICE SENSITIVE
GTGGTG executes license with Conexio Genomics
06/09/12PRICE SENSITIVE
GTGGTG files suit against Reproductive Genetics Institute
30/08/12PRICE SENSITIVE
GTG2012 ASX Appendix 4E and audited Financial Report
28/08/12PRICE SENSITIVE
GTGGenetic Technologies receives CE mark approval for BREVAGen
08/08/12PRICE SENSITIVE
GTGAppendix 4C - quarterly
30/07/12PRICE SENSITIVE
GTGBREVAGen cleared for sale in California
26/07/12PRICE SENSITIVE
GTGNon-coding licensing update
09/07/12PRICE SENSITIVE
GTGBREVAGen credentialing update
22/05/12PRICE SENSITIVE
GTGSettlement with GeneSeek
09/05/12PRICE SENSITIVE
GTGAppendix 4C - quarterly
24/04/12PRICE SENSITIVE
GTGImmunAid Pty. Ltd. secures cornerstone funding
13/04/12PRICE SENSITIVE
GTGUpdate on US and Australian gene patenting litigation
29/02/12PRICE SENSITIVE
GTGHalf Yearly Report and Accounts
27/02/12PRICE SENSITIVE
GTG +Conclusion of second patent infringement suit
21/02/12PRICE SENSITIVE
GTGGTG receives CLIA Certificate of Compliance
16/02/12PRICE SENSITIVE
GTGSettlement with Eurofins STA
06/02/12PRICE SENSITIVE
GTGAppendix 4C - quarterly
30/01/12PRICE SENSITIVE
GTGResponse to ASX Price and Volume Query
27/01/12PRICE SENSITIVE
GTGSettlement and License Agreement with AutoImmun Diagnostika
01/12/11PRICE SENSITIVE
GTGImmunAid press release
02/11/11PRICE SENSITIVE
GTGAppendix 4C - quarterly
26/10/11PRICE SENSITIVE
GTGPreliminary Final Report
25/08/11PRICE SENSITIVE
GTGSettlement with Attomol GmbH
25/08/11PRICE SENSITIVE
GTGAppendix 4C - quarterly
29/07/11PRICE SENSITIVE
GTGReinstatement to Official Quotation
22/07/11PRICE SENSITIVE
GTGCompletion of Successful Capital raising
22/07/11PRICE SENSITIVE
GTGResponse to ASX Price Query
22/07/11PRICE SENSITIVE
GTGSuspension from Official Quotation
13/07/11PRICE SENSITIVE
GTGTrading Halt
12/07/11PRICE SENSITIVE
GTGSettlement with Navigenics
28/06/11PRICE SENSITIVE
GTGLaunch of BREVAGen test in US
20/06/11PRICE SENSITIVE
GTGGTG GENE processes first BREVAGen sample
31/05/11PRICE SENSITIVE
GTGShareholder newsletter
30/05/11PRICE SENSITIVE
GTGFiling of further patent infringement suit
26/05/11PRICE SENSITIVE
GTGResponse to ASX Price and Volume Query
11/05/11PRICE SENSITIVE
GTGAppendix 4C - quarterly
28/04/11PRICE SENSITIVE
GTGGenetic Technologies secures CLIA certification
27/04/11PRICE SENSITIVE
GTGCollaboration with global pharmaceutical company
20/04/11PRICE SENSITIVE
GTGSettlement and License Agreement with ViennaLab Diagnostics
14/04/11PRICE SENSITIVE
GTGSuccessful Conclusion of First Assertion Suit
13/04/11PRICE SENSITIVE
GTGSettlement and License Agreement with Orchid Cellmark, Inc.
11/04/11PRICE SENSITIVE
GTGHalf Yearly Report and Accounts
24/02/11PRICE SENSITIVE
GTGExtension of forensics contract
09/02/11PRICE SENSITIVE
GTGAppendix 4C - quarterly
28/01/11PRICE SENSITIVE
GTGMaiden half-year profit
28/01/11PRICE SENSITIVE
GTG +Second patent infringement law suit filed
20/01/11PRICE SENSITIVE
GTG +Settlement of dispute with Sunrise Medical
17/01/11PRICE SENSITIVE
GTGResponse to ASX Query
07/01/11PRICE SENSITIVE
GTGGranting of license to Qiagen
31/12/10PRICE SENSITIVE
GTGSettlement of dispute with Pioneer Hi-Bred
30/11/10PRICE SENSITIVE
GTGGranting of license to Laboratoires Reunis
23/11/10PRICE SENSITIVE
GTGSettlement of dispute with Innogenetics NV
11/11/10PRICE SENSITIVE
GTGValidation of BREVAGen in Journal of NCI
28/10/10PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
3.9¢ 		Change
0.000(0.00%) 		Mkt cap ! $5.671M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0
GTG (ASX) Chart

Top Stories

Power gets set for 1000-metre maiden drilling program in Brazil

Power Minerals Ltd is planning a maiden drilling program to 1000 metres to test targets at its Nióbio project in Brazil
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
US election outcomes: Key economic and market takeaways This week on Money @ Investing, Mitch Olarenshaw and I break down the recent U.S. presidential election, focusing on its effects on the stock market and the broader economic outlook. Here’s what we covered:1. Election results and policy insightsThe Republican Party&CloseCurlyQuote...
Quit before you're fired: Russia bans uranium exports to USA, duplicating extant US ban Russia's ban of uranium exports to the USA came days before Biden allowed Ukraine use long-range missiles.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.